Yanling Jin

Mississauga, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: June 02, 2025

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 20, 2025

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.

Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 19, 2025

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 05, 2024

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.

Journal: JAMA oncology

Published: September 28, 2023

Association of race/ethnicity and insurance with survival in patients with diffuse large B-cell lymphoma in a large real-world cohort.

Association of race/ethnicity and insurance with survival in patients with diffuse large B-cell lymphoma in a large real-world cohort.

Journal: Cancer medicine

Published: September 07, 2022

Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R.

Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R.

Journal: Pharmaceutical statistics

Published: August 03, 2021

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.

Journal: Nature medicine

Published: March 24, 2021

Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? - A systematic review of reviews: an update.

Does the medical literature remain inadequately described despite having reporting guidelines for 21 years? - A systematic review of reviews: an update.

Journal: Journal of multidisciplinary healthcare

Published: October 13, 2018

Enhancing research publications and advancing scientific writing in health research collaborations: sharing lessons learnt from the trenches.

Enhancing research publications and advancing scientific writing in health research collaborations: sharing lessons learnt from the trenches.

Journal: Journal of multidisciplinary healthcare

Published: May 31, 2018

Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey.

Exploring the characteristics, global distribution and reasons for retraction of published articles involving human research participants: a literature survey.

Journal: Journal of multidisciplinary healthcare

Published: February 07, 2018

Key factors of clinical research network capacity building.

Key factors of clinical research network capacity building.

Journal: The journal of venomous animals and toxins including tropical diseases

Published: February 01, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026